Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Savara Inc

Healthcare US SVRA

5.3USD
0.05(0.95%)

Last update at 2026-06-04T20:00:00Z

Day Range

5.245.43
LowHigh

52 Week Range

2.605.70
LowHigh

Fundamentals

  • Previous Close 5.25
  • Market Cap564.50M
  • Volume1026789
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-69.43600M
  • Revenue TTM0.00100M
  • Revenue Per Share TTM-
  • Gross Profit TTM -28.99100M
  • Diluted EPS TTM-0.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -38.15000M -43.01400M -49.61500M -78.17300M -70.02700M
Minority interest - - - - -
Net income -38.94600M -45.29600M -51.09700M -105.02500M -61.51600M
Selling general administrative 10.93M 12.35M 14.26M 13.08M 10.65M
Selling and marketing expenses - - - - -
Gross profit - -0.13600M 0.26M - 0.00000M
Reconciled depreciation 0.17M 0.37M 0.69M 1.01M 0.53M
Ebit -38.83900M -41.47700M -49.30000M -79.02500M -26.66100M
Ebitda -37.87600M -40.26600M -47.71400M -25.01000M -26.13500M
Depreciation and amortization 0.96M 1.21M 1.59M 54.02M 0.53M
Non operating income net other - - -0.31500M 0.85M 0.02M
Operating income -38.83900M -41.47700M -49.30000M -79.02500M -70.04500M
Other operating expenses 38.04M 40.63M 48.66M 52.17M 48.35M
Interest expense 0.09M 2.28M 1.48M -0.07000M 0.01M
Tax provision - - - 0.00000M -8.51100M
Interest income - - - 0.36M 0.02M
Net interest income -0.08800M -2.28200M -1.48200M -0.07000M 0.01M
Extraordinary items - - - - -
Non recurring - - - 26.85M 21.69M
Other items - - - - -
Income tax expense 0.80M 2.28M 1.48M 26.85M -8.51100M
Total revenue 0.00000M 0.00000M 0.26M 0.00000M 0.00000M
Total operating expenses 38.04M 40.63M 48.66M 52.17M 48.35M
Cost of revenue - 0.14M - - 0.00000M
Total other income expense net 0.69M -1.53700M -0.31500M 0.85M -21.69200M
Discontinued operations - - - - -
Net income from continuing ops -38.15000M -43.01400M -49.61500M -78.17300M -61.51600M
Net income applicable to common shares - -43.01400M -49.61500M -78.17300M -61.51600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 177.56M 139.78M 176.60M 97.75M 136.20M
Intangible assets 10.96M 10.66M 11.27M 12.22M 11.11M
Earning assets - - - - -
Other current assets 2.62M 0.07M 3.83M 2.93M 2.31M
Total liab 37.19M 32.00M 32.10M 33.36M 34.51M
Total stockholder equity 140.37M 107.78M 144.50M 64.38M 101.70M
Deferred long term liab - - - 12.22M 11.11M
Other current liab 6.95M 4.47M 4.75M 5.40M 5.03M
Common stock 0.14M 0.12M 0.12M 0.06M 0.05M
Capital stock 0.14M 0.12M 0.12M 0.06M 0.05M
Retained earnings -393.36900M -338.67100M -300.52100M -257.50700M -207.89200M
Other liab - - 0.02M 0.08M 0.27M
Good will - - - - 0.00000M
Other assets 0.00000M - - 12.47M 11.11M
Cash 26.59M 52.10M 34.01M 22.88M 49.80M
Cash and equivalents - - - - -
Total current liabilities 10.60M 5.87M 14.66M 8.17M 10.88M
Current deferred revenue - - - - -
Net debt 0.15M -25.95800M -8.22100M 2.40M -24.25200M
Short term debt 0.14M 0.06M 8.47M 0.18M 2.44M
Short long term debt - - 8.33M - 2.00M
Short long term debt total 26.74M 26.14M 25.79M 25.28M 25.55M
Other stockholder equity 533.87M 446.94M 444.90M 320.89M 309.56M
Property plant equipment - - 0.32M 0.16M 0.35M
Total current assets 165.95M 128.95M 165.00M 85.12M 124.07M
Long term investments - - - - -
Net tangible assets - - 133.22M 64.38M 101.70M
Short term investments 135.73M 73.78M 127.16M 59.31M 71.96M
Net receivables 1.00M 0.95M 1.14M 1.70M 1.62M
Long term debt 26.35M 26.08M 17.32M 25.10M 23.11M
Inventory 0.00000M 2.05M -1.14400M -1.69500M -1.61700M
Accounts payable 3.50M 1.33M 1.44M 2.60M 3.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.27100M -0.60500M 0.00500M 0.94M -0.01700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -257.50700M -207.89200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.39M 0.12M 0.25M 0.25M 0.67M
Deferred long term asset charges - - - - -
Non current assets total 11.62M 10.82M 11.60M 12.62M 12.14M
Capital lease obligations 0.14M 0.06M 0.14M 0.18M 0.44M
Long term debt total - - - 25.10M 23.11M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 52.65M -69.45600M 98.43M 138.83M -13.47800M
Change to liabilities - -1.76300M -0.43100M 0.57M 1.55M
Total cashflows from investing activities - -69.45600M 9.05M 15.74M -13.61900M
Net borrowings - - -0.51400M -0.04100M 8.82M
Total cash from financing activities 0.09M 120.81M 3.69M 54.91M 55.19M
Change to operating activities - -1.08300M -0.56500M 0.28M 0.90M
Net income -38.15000M -43.01400M -49.61500M -78.17300M -61.51600M
Change in cash 18.09M 11.13M -26.92400M 25.50M 2.18M
Begin period cash flow 34.01M 22.88M 49.80M 24.30M 22.12M
End period cash flow 52.10M 34.01M 22.88M 49.80M 24.30M
Total cash from operating activities -34.55400M -40.08100M -39.83600M -45.12300M -39.27500M
Issuance of capital stock 0.00000M 122.23M 2.29M 54.84M 46.30M
Depreciation 0.17M 0.37M 0.69M 1.01M 0.53M
Other cashflows from investing activities - - -89.33000M -122.94500M -13.47800M
Dividends paid - - -2.12000M - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock -0.00300M -0.07800M 2.12M 54.95M 46.35M
Other cashflows from financing activities 26.44M -1.34700M 1.91M 0.11M 9.44M
Change to netincome - 4.86M 10.32M 31.63M 18.64M
Capital expenditures 0.00900M 0.06M 3.29M 0.15M 0.14M
Change receivables - - - - -
Cash flows other operating - - -0.86800M -0.17300M 2.60M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -27.09400M 25.52M 2.30M
Change in working capital 0.96M -2.84600M -1.70500M 0.85M 2.45M
Stock based compensation 2.04M 3.26M 5.11M 4.44M 3.74M
Other non cash items 0.43M 0.45M 5.90M 0.77M 22.59M
Free cash flow -34.56300M -40.13800M -43.13000M -45.27100M -39.41600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SVRA
Savara Inc		 0.05 0.95% 5.30 - - 131146.00 4.99 11.91 -9.5635
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

Savara Inc

1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047

Key Executives

Name Title Year Born
Mr. Matthew Pauls Chairman & CEO 1971
Mr. David L. Lowrance CPA CFO & Sec. 1968
Ms. Kate McCabe Sr. VP of Legal Affairs NA
Ms. Anne Erickson Sr. VP & Head of Global Bus. Operations NA
Brian Maurer Head of Clinical Operations NA
Mr. Charles LaPree Sr. VP of Global Regulatory Affairs & Quality Assurance NA
Dr. Peter Clarke Ph.D. Exec. VP of Global Technical Operations 1960
Dr. Raymond Dennis Pratt FACP, M.D. Chief Medical Officer 1951
Mr. Matthew Pauls J.D., M.B.A. Chairman & CEO 1971
Mr. David L. Lowrance CPA CFO, Chief Administrative Officer & Secretary 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.